iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.

iBio, Inc.

Kebotix provides R&D solutions through enterprise AI customized for materials discovery, leveraging cloud technologies, machine learning, and automation.

Kebotix

iBio develops antibody therapeutics, focusing on precision antibody identification, optimization, and collaboration for drug discovery and development. Self-described as utilizing AI and machine learning in their processes.

Metric
Company Name	iBio, Inc.	Kebotix
Symbol	IBIO
MSH ID	COM:IBIOINC	COM:KEBOTIX
Market	STOCKS	PRIVATE
Sector	Healthcare	Technology
Industry	Biotechnology	Materials Science
Country	US	US
Stage		Venture Round
Employee Count	26
Website	ibioinc.com	kebotix.com
LinkedIn
Founders

Metric
Market Cap	17.07M
Enterprise Value
Monthly Web Traffic		187
Web Traffic Growth		-0.83
Valuation
Raised Capital		5.00M

Metric
Revenue	225K
Revenue (LTM)
Revenue (NTM)
Gross Profit	225K
EBITDA	-15.44M
Operating Income	-15.44M
Net Income	-24.91M
EPS	-6.50
Diluted EPS	-6.50
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin	-73.93
EBITDA Margin	-68.64
Net Profit Margin	-110.70
Return on Equity	-1.45
Return on Assets	-0.46
Return on Capital Employed	-0.60

COM:IBIOINC

iBio

Last Close

2.45

22/11 21:00

Market Cap

17.07M

Beta: -

Volume Today

307.26K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-0.51
P/B Ratio	2.00
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	430.32
EV Multiple	0.51

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding	5.48K
Operating Cycle	102.96K
Cash Conversion Cycle	102.51K
Asset Turnover	0.01

Metric
Operating Cash Flow	-18.55M
Free Cash Flow	-18.76M
Cash Flow to Debt	-1.07
Operating Cash Flow/Sales	-82.46
Free Cash Flow Yield	-16.22

Metric
Cash & Equivalents	14.21M
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization	0.64
Debt to Assets	0.44
Current Ratio	1.11
Quick Ratio	4.08

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	78.68
R&D to Revenue	187.70
SG&A to Revenue	349.50